Lisinopril Dihydrate: Precision Long-Acting ACE Inhibitor for Hypertension and Cardiovascular Research

Executive Summary: Lisinopril dihydrate is a dihydrate form of the long-acting ACE inhibitor, lisinopril, with an IC₅₀ of 4.7 nM against ACE in vitro (https://www.apexbt.com/lisinopril-dihydrate.html). This compound acts by inhibiting the conversion of angiotensin I to angiotensin II, reducing blood pressure through vasodilation and decreased aldosterone-mediated fluid retention (Tieku & Hooper 1992, DOI). Lisinopril dihydrate is water soluble (≥2.46 mg/mL with warming/ultrasonics) and stable when stored desiccated at room temperature. It is extensively used for modeling hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy in preclinical research (see: mechanistic insight). Quality is confirmed by mass spectrometry and NMR, with a purity of 98% (APExBIO B3290 kit).

Biological Rationale

Lisinopril dihydrate is derived from lisinopril, a lysine analogue of MK 421. It targets the renin-angiotensin system (RAS), a central regulator of blood pressure and fluid balance. Angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of angiotensin I (inactive decapeptide) to angiotensin II, a potent vasoconstrictor (Tieku & Hooper 1992, DOI). Inhibition of ACE thus reduces angiotensin II and aldosterone levels, leading to vasodilation, decreased sodium retention, and lower blood pressure. This mechanistic pathway is conserved in mammalian models and is a validated target for cardiovascular and nephrology research.

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate exerts its effects by binding to the active site of ACE, competitively inhibiting its peptidase activity. The compound's IC₅₀ of 4.7 nM demonstrates high affinity and selectivity for ACE under standard in vitro assay conditions (pH 8.3, 37°C, 30 min) (https://www.apexbt.com/lisinopril-dihydrate.html). By preventing the formation of angiotensin II, lisinopril dihydrate interrupts downstream signaling that promotes vasoconstriction and aldosterone secretion. This results in reduced systemic vascular resistance and diuresis. Notably, the dihydrate form offers enhanced handling and solubility for laboratory workflows. APExBIO ensures product quality via mass spectrometry and NMR validation, supporting reproducible research.

Evidence & Benchmarks

• Inhibition of ACE by lisinopril dihydrate is highly selective, with an IC₅₀ of 4.7 nM in standardized activity assays (https://www.apexbt.com/lisinopril-dihydrate.html).
• ACE inhibition by lisinopril dihydrate leads to a dose-dependent decrease in angiotensin II and aldosterone levels, as demonstrated in mammalian cell and animal models (Tieku & Hooper 1992, DOI).
• Unlike bestatin or other broad-spectrum peptidase inhibitors, lisinopril dihydrate does not inhibit aminopeptidase A, N, or W, confirming its high target specificity (Tieku & Hooper 1992, DOI).
• The dihydrate form is soluble in water at ≥2.46 mg/mL with gentle warming and ultrasonication, but insoluble in ethanol, supporting aqueous-based workflows (https://www.apexbt.com/lisinopril-dihydrate.html).
• APExBIO's Lisinopril dihydrate (B3290) is supplied at ≥98% purity, with batch-level validation by MS and NMR (https://www.apexbt.com/lisinopril-dihydrate.html).

Applications, Limits & Misconceptions

Lisinopril dihydrate is established for use in the following research contexts:

• Hypertension models: Validated for pharmacodynamic and mechanistic studies of blood pressure regulation (see Precision ACE Inhibitor; this article extends those findings by providing explicit physicochemical and workflow benchmarks).
• Heart failure: Used to probe cardiac remodeling and hemodynamics via modulation of the RAS.
• Acute myocardial infarction: Deployed to study infarct size, reperfusion injury, and post-MI remodeling.
• Diabetic nephropathy: Models RAS-mediated glomerular injury and sclerosis.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate is not effective against non-ACE peptidases (e.g., aminopeptidase N, A, W), and should not be used to probe their biology (Tieku & Hooper 1992, DOI).
• It is insoluble in ethanol and other organic solvents; improper solvent choice can reduce assay performance.
• Long-term storage of aqueous solutions (>1 week) is not recommended due to potential hydrolysis or degradation; prepare fresh solutions for critical applications (https://www.apexbt.com/lisinopril-dihydrate.html).
• Not indicated for in vivo use in humans; this compound is for research use only.
• Some side effects in animal models (e.g., renal impairment at high doses) may not extrapolate to human biology.

For advanced mechanistic perspectives and translational strategy, see Lisinopril Dihydrate: Mechanistic Insight. This article expands upon enzyme selectivity and workflow integration not covered in prior reviews.

Workflow Integration & Parameters

• Solubility: Dissolves in water at ≥2.46 mg/mL with gentle warming and ultrasonication; insoluble in ethanol.
• Storage: Store desiccated at room temperature. Avoid long-term storage of aqueous solutions.
• Purity & QC: Each lot validated by mass spectrometry and NMR. Purity ≥98% (APExBIO B3290).
• Shipping: Ships with blue ice for stability.
• Recommended use: Prepare fresh solutions for experiments. Avoid exposure to strong acids/bases.

For protocol optimization and troubleshooting, refer to Lisinopril Dihydrate: Long-Acting ACE Inhibitor, which provides additional data on purity and reproducibility benchmarks. This article extends those standards by including explicit solubility and storage guidelines.

Conclusion & Outlook

Lisinopril dihydrate is a validated, highly selective ACE inhibitor for preclinical research in cardiovascular, renal, and metabolic disease models. Its physicochemical and pharmacological properties support robust, reproducible experimentation in the study of the renin-angiotensin system. APExBIO supplies the compound with comprehensive quality control, enabling advanced mechanistic and translational research. Ongoing studies continue to define its role in emerging disease models, emphasizing the need for precise workflow integration and target specificity.